Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremie Calais

Showing results (111-120 of 207) with videos related to

Pageof 21
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal AdenocarcinomaMatthias R Benz, Wesley R Armstrong, Francesco Ceci, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2025
Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical TherapyAdrien Holzgreve, Christine E Mona, Koichiro Kimura, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
The Prostate|November 29, 2022
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meetingAndrea K Miyahira, Jessica E Hawley, Remi Adelaiye-Ogala, et al.
European Urology|March 17, 2024
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical TrialJohn Nikitas, Matthew Rettig, John Shen, et al.
Frontiers in Medicine|June 26, 2020
Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration MethodBlandine Truffault, David Bourhis, Anne Chaput, et al.
Scientific Reports|October 17, 2024
Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapyJohn Nikitas, Andrei Gafita, Matthias R Benz, et al.
EJNMMI Research|October 1, 2022
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225Catherine Meyer, Vikas Prasad, Andreea Stuparu, et al.
BJU International|February 16, 2023
LUNAR: a randomized Phase 2 study of <sup>177</sup> Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol)Ting Martin Ma, Johannes Czernin, Carol Felix, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
The Impact of Monosodium Glutamate on <sup>68</sup>Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging StudyWesley R Armstrong, Andrei Gafita, Shaojun Zhu, et al.
Pageof 21

Showing results (111-120 of 207) with videos related to

Sort By:
Pageof 21
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal AdenocarcinomaMatthias R Benz, Wesley R Armstrong, Francesco Ceci, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2025
Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical TherapyAdrien Holzgreve, Christine E Mona, Koichiro Kimura, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
The Prostate|November 29, 2022
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meetingAndrea K Miyahira, Jessica E Hawley, Remi Adelaiye-Ogala, et al.
European Urology|March 17, 2024
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical TrialJohn Nikitas, Matthew Rettig, John Shen, et al.
Frontiers in Medicine|June 26, 2020
Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration MethodBlandine Truffault, David Bourhis, Anne Chaput, et al.
Scientific Reports|October 17, 2024
Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapyJohn Nikitas, Andrei Gafita, Matthias R Benz, et al.
EJNMMI Research|October 1, 2022
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225Catherine Meyer, Vikas Prasad, Andreea Stuparu, et al.
BJU International|February 16, 2023
LUNAR: a randomized Phase 2 study of <sup>177</sup> Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol)Ting Martin Ma, Johannes Czernin, Carol Felix, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
The Impact of Monosodium Glutamate on <sup>68</sup>Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging StudyWesley R Armstrong, Andrei Gafita, Shaojun Zhu, et al.
Pageof 21